Previous 10 | Next 10 |
– Results of retrospective analysis demonstrate a 61% intracranial response rate in patients with progressing brain metastases – – Data to be presented during the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium ...
With a median follow-up of two years, OPDIVO in combination with CABOMETYX continues to demonstrate superior progression-free survival, overall survival and objective response rate compared to sunitinib Patients treated with OPDIVO in combination with CABOM...
Junshi Bio out-licensed US-Canada rights for its anti-PD-1 antibody to Coherus Bio in an agreement worth up to $1.1 billion. Adagene will license its SAFEbody™ technology platform to Exelixis (EXEL) for use in Exelixis' ADC preclinical pipeline. Innovent Biologics and its p...
- Presentation to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in a fireside chat as part of the Guggenheim Healthcare Talks On...
- Exelixis will utilize Adagene’s proprietary SAFEbody ™ technology to develop novel masked antibody-drug conjugates (ADCs) with potential for improved therapeutic index - Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license...
– Conference Call and Webcast to Follow at 5:00 p.m. EST / 2:00 p.m. PST – Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2020 financial results will be released on Wednesday, February 10, 2021 after the markets clos...
Exelixis (EXEL) has initiated Phase 1 trial evaluating of XL102 alone or in combination with other anti-cancer agents in patients with inoperable locally advanced or metastatic solid tumors.XL102 is a potent, selective and orally bioavailable inhibitor of cyclin-dependent kinase 7, an importa...
– Encouraging preclinical data presented in 2020 support advancement to clinical evaluation for XL102, Exelixis’ novel oral CDK7 inhibitor – – Expansion phase of the trial will include cohorts for ovarian, breast and prostate cancers – ...
Exelixis (NASDAQ: EXEL) is charging into the weekend on a high note. On Friday, the company announced that the Food and Drug Administration approved its drug Cabometyx (also known as Cometriq) for first-line treatment of patients with advanced renal cell carcinoma (RCC), in combinat...
Exelixis ([[EXEL]] +2.6%) announces that the FDA has approved its CABOMETYX (cabozantinib) drug in combination with Bristol-Myers Squibb's ([[BMY]] +1.2%) OPDIVO (nivolumab) for treating patients with advanced renal cell carcinoma ((RCC)) in the first-line setting.The...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...